Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Erin Yoder"'
Autor:
Brian Hoxeng, Andrea Menicucci, Shiyu Wang, William Audeh, Erin Yoder, Jennifer Wei, Joseph McKelley
Publikováno v:
Cancer Research. 81:PS6-19
Background: Pre-operative/neoadjuvant treatment utilization in early-stage breast cancer has been increasing, particularly during the COVID-19 pandemic. With goals of minimizing potential exposure to SARS-COV-2, as well as resource rationing, physici
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::788e12781e203fffef390b682d419e00
https://doi.org/10.1158/1538-7445.sabcs20-ps6-19
https://doi.org/10.1158/1538-7445.sabcs20-ps6-19
Autor:
Joanne E. Mortimer, James Waisman, Daphne Stewart, Erin Yoder, Veronica Jones, Bastiaan van der Baan, Sierra Min Li, Andrea Menicucci, Aileen Tang, Christina Yeon, Susan E. Yost, Paul Frankel, Yuan Yuan, George Somlo, Jin Sun Lee, John H. Yim, Sahra Uygun, Norma Martinez, Laura Kruper, Daniel Schmolze, Christopher Ruel, Kim Robinson
Publikováno v:
Oncologist
BackgroundIn this phase II clinical trial, we evaluated the efficacy of the nonanthracycline combination of carboplatin and nab-paclitaxel in early stage triple-negative breast cancer (TNBC).Patients and MethodsPatients with newly diagnosed stage II
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::636939ca9c553a4b0ce6b0cbd030a0e1
https://doi.org/10.1002/onco.13574
https://doi.org/10.1002/onco.13574
Autor:
Mehran Habibi, Nina D'Abreo, Adam Brufsky, William Audeh, Pat Whitworth, Gordan Srkalovic, Ian Grady, Erin Yoder, Bastiaan van der Baan, Thomas Lomis, Jennifer A. Crozier, Heather M. Kling, Charles E. Cox, Sarah Untch
Publikováno v:
Cancer Research. 80:OT3-17
Background discussion: Genomic signatures are revolutionizing the definition, identification, and treatment of breast cancer. To precisely stratify breast cancers into actionable subgroups, full genome (FG) expression data and matching clinical data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::caba9080f1827d0fc2e97c252b465ba9
https://doi.org/10.1158/1538-7445.sabcs19-ot3-17-02
https://doi.org/10.1158/1538-7445.sabcs19-ot3-17-02
Autor:
Raquel Nunes, William Audeh, Sahra Uygun, Erin Yoder, Sarah Untch, Lisa Blumencranz, Heather M. Kling, Jennifer A. Crozier
Publikováno v:
Cancer Research. 80:P2-10
Background: Breast cancer (BC) mortality is higher in African-American women (AA) than in Caucasian women (CA). AA are also diagnosed at a younger age, have more aggressive subtypes and greater incidence of metabolic dysfunction such as obesity and d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9db19be097b5393ff5162c7fdc4d33d2
https://doi.org/10.1158/1538-7445.sabcs19-p2-10-08
https://doi.org/10.1158/1538-7445.sabcs19-p2-10-08
Autor:
Barone J, Shiyu Wang, Mee S, Andrea Menicucci, Cheong A, Yang S, C. Finn, P Whitworth, Anke T. Witteveen, Corcoran K, Dauer P, Huynh Y, Jennifer A. Crozier, Erin Yoder, Jennifer Wei, Tran A, van der Baan B, Maganini R, Christa Dreezen, William Audeh, Annuska M. Glas, Ruby J, Falk J
IntroductionWith an increase in neoadjuvant therapy recommendations for most early-stage breast cancer patients due to the COVID-19 pandemic, it has become increasingly imperative to ensure that molecular diagnostic assays provide reliable results fr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a2dd6b7267ebd8c7487f973061c5b646
https://doi.org/10.1101/2021.05.28.21257887
https://doi.org/10.1101/2021.05.28.21257887
Autor:
Erin Yoder, P Baron, Lisa Blumencranz, Thomas Lomis, Adam Brufsky, Gordan Srkalovic, Sarah Untch, Jennifer A. Crozier, Peter W. Blumencranz, P Whitworth, E Rehmus, William Audeh, B Mavromatis, LL Lee, Ian Grady
Publikováno v:
Cancer Research. 79:OT1-13
BACKGROUND: Genomic signatures are revolutionizing the definition, identification, and treatment of breast cancer subtypes. The ability of genomic signatures to enable fine grained stratification of breast cancers to the granular disease level is sti
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26a0584f8d7e31d63f0b7eb59445164e
https://doi.org/10.1158/1538-7445.sabcs18-ot1-13-01
https://doi.org/10.1158/1538-7445.sabcs18-ot1-13-01
Autor:
J Srinivasiah, Reshma Mahtani, Hatem Soliman, B Mavromatis, Erin Yoder, M Kassar, Gordan Srkalovic, William Audeh, Ellis G. Levine, V Shah, R Gabordi, E Rehmus, Rubina Qamar
Publikováno v:
Cancer Research. 78:P6-13
Background: IMPACt is a prospective, case-only study to measure the effect of MammaPrint (MP) and BluePrint (BP) on treatment decisions in breast cancer patients. Here, we report the results of the primary objective in women aged ≥18 years with his
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d537c9186d639722932528732bef472c
https://doi.org/10.1158/1538-7445.sabcs17-p6-13-04
https://doi.org/10.1158/1538-7445.sabcs17-p6-13-04
Autor:
Peter D. Beitsch, Pat Whitworth, William Audeh, Paul L. Baron, Erin Yoder, René Bernards, Floris H. Groenendijk, Winand N.M. Dinjens, Tina Treece
Publikováno v:
npj Breast Cancer, 5:15. Nature Publishing Group
npj Breast Cancer, Vol 5, Iss 1, Pp 1-8 (2019)
NPJ Breast Cancer
npj Breast Cancer, Vol 5, Iss 1, Pp 1-8 (2019)
NPJ Breast Cancer
Immunohistochemically ER-positive HER2-negative (ER+HER2−) breast cancers are classified clinically as Luminal-type. We showed previously that molecular subtyping using the 80-gene signature (80-GS) reclassified a subset of ER+HER2− tumors to mol
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5eea456ffe27b4284b4658c3d421eb29
https://pure.eur.nl/en/publications/891dec41-d540-41d9-b6fe-996e7ff22abc
https://pure.eur.nl/en/publications/891dec41-d540-41d9-b6fe-996e7ff22abc
Autor:
Erin Yoder, Lorenza Mittempergher, Karen L. Tedesco, Apurva N. Shah, William Audeh, Abirami Sivapiragasam, Andrea Menicucci, Virginia G. Kaklamani, Michelle L. Bolner, Josien C. Haan, Yuan Yuan, Shiyu Wang, Cathy Graham, Jennifer A. Crozier
Publikováno v:
Cancer Research. 81:PS18-05
Background: Triple negative breast cancers (TNBC) are more aggressive, have a worse prognosis, and few targeted therapies compared to other BC subtypes. TNBC is molecularly heterogeneous, with at least 4 distinct subtypes: basal-like immune-activated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::867ed3a6e515c9cd851d89b0c7390b83
https://doi.org/10.1158/1538-7445.sabcs20-ps18-05
https://doi.org/10.1158/1538-7445.sabcs20-ps18-05
Autor:
Kalyan Banda, William Audeh, Beth Lesnikoski, Charles E. Cox, Andrea Menicucci, Jennifer A. Crozier, Julie Barone, Robert Maganini, Erin Yoder, Benjamin Nota, Amy Truitt, Thomas Lomis, Sami Diab, Ian Grady
Publikováno v:
Cancer Research. 81:PS14-11
Background: Male breast cancer (MaBC) is rare, comprising Methods: This analysis included a total of 817 breast tumor samples sent to Agendia, Inc. (Irvine, CA) for MP and BP testing. Full-transcriptome microarray data were available for 1) a subset
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0f44c8f9c1642885c4d1c6f5b8a8f692
https://doi.org/10.1158/1538-7445.sabcs20-ps14-11
https://doi.org/10.1158/1538-7445.sabcs20-ps14-11